Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Wiseguyreports.Com Adds “Insulin Delivery Systems – Global Market Demand, Growth, Opportunities, Manufacturers, Analysis of Top Key Players and Forecast to 2022” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday
Let’s just say it hasn’t been a great week for Novo Nordisk. After losing out to higher bidder Sanofi on a buyout of Ablynx, the Danish drugmaker Thursday rolled out fourth-quarter results and 2018 guidance that Oddo BHF analyst Sebastien Malafosse called “disappointing” in a note to clients.
Actor Anthony Anderson is a comedian, but when it comes to diabetes, he is a serious advocate. He's partnered with Novo Nordisk to create the “Get Real About Diabetes” disease awareness campaign, and as part of that effort he wrote a Type 2 diabetes diagnosis episode into the plot of his hit comedy …
Novo Nordisk is about to take on a task that’s so far foiled its peers. The Danish drugmaker is aiming to expand the global obesity market, both by launching its GLP-1 drug Saxenda in additional countries and by lobbying to get obesity recognized as a chronic disease.